RJFSA
VKTX icon

Raymond James Financial Services Advisors’s Viking Therapeutics VKTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$8.25M Buy
130,306
+33,401
+34% +$1.96M 0.01% 961
2024
Q2 		$5.14M Sell
96,905
-999
-1% -$65.5K 0.01% 1151
2024
Q1 		$8.03M Sell
97,904
-49,548
-34% -$2.2M 0.01% 912
2023
Q4 		$2.74M Buy
147,452
+13,097
+10% +$171K ﹤0.01% 1398
2023
Q3 		$1.49M Sell
134,355
-8,849
-6% -$127K ﹤0.01% 1681
2023
Q2 		$2.32M Buy
143,204
+39,857
+39% +$835K ﹤0.01% 1427
2023
Q1 		$1.72M Sell
103,347
-25,360
-20% -$262K ﹤0.01% 1574
2022
Q4 		$1.21M Sell
128,707
-14,500
-10% -$64.7K ﹤0.01% 1714
2022
Q3 		$390K Buy
143,207
+1,626
+1% +$5.33K ﹤0.01% 2405
2022
Q2 		$409K Sell
141,581
-2,951
-2% -$7.3K ﹤0.01% 2404
2022
Q1 		$434K Sell
144,532
-32,117
-18% -$115K ﹤0.01% 2463
2021
Q4 		$813K Sell
176,649
-4,874
-3% -$27.3K ﹤0.01% 2096
2021
Q3 		$1.14M Buy
181,523
+18,860
+12% +$117K ﹤0.01% 1869
2021
Q2 		$974K Sell
162,663
-770
-0.5% -$4.57K ﹤0.01% 1961
2021
Q1 		$1.03M Buy
163,433
+28,588
+21% +$201K ﹤0.01% 1840
2020
Q4 		$759K Buy
134,845
+21,505
+19% +$130K ﹤0.01% 1886
2020
Q3 		$660K Sell
113,340
-9,798
-8% -$67.5K ﹤0.01% 1806
2020
Q2 		$888K Buy
123,138
+39,136
+47% +$260K ﹤0.01% 1565
2020
Q1 		$393K Buy
84,002
+12,654
+18% +$77.8K ﹤0.01% 1682
2019
Q4 		$572K Sell
71,348
-301
-0.4% -$2.19K ﹤0.01% 1883
2019
Q3 		$493K Buy
71,649
+24,171
+51% +$180K ﹤0.01% 1909
2019
Q2 		$394K Buy
47,478
+12,764
+37% +$109K ﹤0.01% 2079
2019
Q1 		$345K Buy
34,714
+12,453
+56% +$104K ﹤0.01% 2148
2018
Q4 		$170K Buy
+22,261
New +$266K ﹤0.01% 2308

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Raymond James Financial Services Advisors's VKTX Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Viking Therapeutics (VKTX) stake by 34% in Q3 2024, buying an estimated $1.96M and bringing the position to 130,306 shares worth $8.25M. The position accounts for 0.01% of the portfolio, ranked #961.

Raymond James Financial Services Advisors first reported a position in VKTX in Q4 2018 and has held it in 24 quarters since. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Raymond James Financial Services Advisors held 130,306 shares of Viking Therapeutics worth $8.25M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 33,401 Viking Therapeutics shares in Q3 2024, an estimated $1.96M.
  • Viking Therapeutics made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #961 holding.
  • Raymond James Financial Services Advisors first reported a position in Viking Therapeutics in Q4 2018 and has held it in 24 quarters since.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.